INTUITIVE SURGICAL INC (IUI1.DE) Fundamental Analysis & Valuation

FRA:IUI1 • US46120E6023

Current stock price

384.95 EUR
-4 (-1.03%)
Last:

This IUI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. IUI1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year IUI1 was profitable.
  • In the past year IUI1 had a positive cash flow from operations.
  • Each year in the past 5 years IUI1 has been profitable.
  • In the past 5 years IUI1 always reported a positive cash flow from operatings.
IUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFIUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

1.2 Ratios

  • IUI1 has a better Return On Assets (13.96%) than 95.24% of its industry peers.
  • IUI1 has a Return On Equity of 16.02%. This is amongst the best in the industry. IUI1 outperforms 87.30% of its industry peers.
  • The Return On Invested Capital of IUI1 (13.95%) is better than 92.06% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for IUI1 is above the industry average of 10.21%.
  • The last Return On Invested Capital (13.95%) for IUI1 is above the 3 year average (12.43%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 13.96%
ROE 16.02%
ROIC 13.95%
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
IUI1.DE Yearly ROA, ROE, ROICIUI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • With an excellent Profit Margin value of 28.38%, IUI1 belongs to the best of the industry, outperforming 98.41% of the companies in the same industry.
  • IUI1's Profit Margin has improved in the last couple of years.
  • IUI1's Operating Margin of 29.35% is amongst the best of the industry. IUI1 outperforms 98.41% of its industry peers.
  • In the last couple of years the Operating Margin of IUI1 has grown nicely.
  • IUI1 has a Gross Margin of 66.00%. This is in the better half of the industry: IUI1 outperforms 74.60% of its industry peers.
  • In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
Industry RankSector Rank
OM 29.35%
PM (TTM) 28.38%
GM 66%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
IUI1.DE Yearly Profit, Operating, Gross MarginsIUI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. IUI1.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IUI1 is creating some value.
  • The number of shares outstanding for IUI1 has been reduced compared to 1 year ago.
  • IUI1 has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IUI1.DE Yearly Shares OutstandingIUI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
IUI1.DE Yearly Total Debt VS Total AssetsIUI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B

2.2 Solvency

  • IUI1 has an Altman-Z score of 38.37. This indicates that IUI1 is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of IUI1 (38.37) is better than 98.41% of its industry peers.
  • There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 38.37
ROIC/WACC1.56
WACC8.95%
IUI1.DE Yearly LT Debt VS Equity VS FCFIUI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 4.87 indicates that IUI1 has no problem at all paying its short term obligations.
  • IUI1 has a better Current ratio (4.87) than 93.65% of its industry peers.
  • A Quick Ratio of 3.96 indicates that IUI1 has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 3.96, IUI1 belongs to the best of the industry, outperforming 95.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.87
Quick Ratio 3.96
IUI1.DE Yearly Current Assets VS Current LiabilitesIUI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. IUI1.DE Growth Analysis

3.1 Past

  • IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.83%, which is quite impressive.
  • The Earnings Per Share has been growing by 21.42% on average over the past years. This is a very strong growth
  • IUI1 shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.51%.
  • The Revenue has been growing by 18.22% on average over the past years. This is quite good.
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%

3.2 Future

  • Based on estimates for the next years, IUI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.58% on average per year.
  • IUI1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.90% yearly.
EPS Next Y14.43%
EPS Next 2Y14.29%
EPS Next 3Y14.44%
EPS Next 5Y13.58%
Revenue Next Year15.83%
Revenue Next 2Y14.84%
Revenue Next 3Y14.56%
Revenue Next 5Y12.9%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IUI1.DE Yearly Revenue VS EstimatesIUI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
IUI1.DE Yearly EPS VS EstimatesIUI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

2

4. IUI1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 50.45, the valuation of IUI1 can be described as expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 60.32% of the companies listed in the same industry.
  • IUI1's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.78.
  • With a Price/Forward Earnings ratio of 44.12, IUI1 can be considered very expensive at the moment.
  • IUI1's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. IUI1 is more expensive than 66.67% of the companies in the same industry.
  • IUI1 is valuated expensively when we compare the Price/Forward Earnings ratio to 23.54, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 50.45
Fwd PE 44.12
IUI1.DE Price Earnings VS Forward Price EarningsIUI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 65.08% of the companies listed in the same industry.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as IUI1.
Industry RankSector Rank
P/FCF 64.29
EV/EBITDA 41.7
IUI1.DE Per share dataIUI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of IUI1 may justify a higher PE ratio.
  • IUI1's earnings are expected to grow with 14.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.5
PEG (5Y)2.36
EPS Next 2Y14.29%
EPS Next 3Y14.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IUI1.DE Dividend Analysis

5.1 Amount

  • No dividends for IUI1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IUI1.DE Fundamentals: All Metrics, Ratios and Statistics

INTUITIVE SURGICAL INC

FRA:IUI1 (4/10/2026, 7:00:00 PM)

384.95

-4 (-1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-22
Earnings (Next)04-21
Inst Owners88.75%
Inst Owner ChangeN/A
Ins Owners0.46%
Ins Owner ChangeN/A
Market Cap136.72B
Revenue(TTM)10.06B
Net Income(TTM)2.86B
Analysts79.02
Price Target543.14 (41.09%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.28%
Min EPS beat(2)9.85%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)10.81%
Min EPS beat(4)3.05%
Max EPS beat(4)18.71%
EPS beat(8)8
Avg EPS beat(8)11.52%
EPS beat(12)12
Avg EPS beat(12)8.73%
EPS beat(16)14
Avg EPS beat(16)6.39%
Revenue beat(2)2
Avg Revenue beat(2)2.19%
Min Revenue beat(2)2.17%
Max Revenue beat(2)2.22%
Revenue beat(4)4
Avg Revenue beat(4)1.83%
Min Revenue beat(4)1.09%
Max Revenue beat(4)2.22%
Revenue beat(8)5
Avg Revenue beat(8)1.43%
Revenue beat(12)7
Avg Revenue beat(12)0.96%
Revenue beat(16)9
Avg Revenue beat(16)0.46%
PT rev (1m)2.97%
PT rev (3m)3.73%
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)0.26%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)2.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.99%
Valuation
Industry RankSector Rank
PE 50.45
Fwd PE 44.12
P/S 15.91
P/FCF 64.29
P/OCF 52.83
P/B 8.98
P/tB 9.18
EV/EBITDA 41.7
EPS(TTM)7.63
EY1.98%
EPS(NY)8.73
Fwd EY2.27%
FCF(TTM)5.99
FCFY1.56%
OCF(TTM)7.29
OCFY1.89%
SpS24.2
BVpS42.85
TBVpS41.92
PEG (NY)3.5
PEG (5Y)2.36
Graham Number85.77
Profitability
Industry RankSector Rank
ROA 13.96%
ROE 16.02%
ROCE 16.01%
ROIC 13.95%
ROICexc 20.73%
ROICexgc 21.4%
OM 29.35%
PM (TTM) 28.38%
GM 66%
FCFM 24.75%
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
ROICexc(3y)18.4%
ROICexc(5y)18.81%
ROICexgc(3y)19.07%
ROICexgc(5y)19.65%
ROCE(3y)14.27%
ROCE(5y)14.28%
ROICexgc growth 3Y2.03%
ROICexgc growth 5Y0.92%
ROICexc growth 3Y2.86%
ROICexc growth 5Y2.05%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 79.72%
Cap/Sales 5.36%
Interest Coverage 250
Cash Conversion 83.46%
Profit Quality 87.21%
Current Ratio 4.87
Quick Ratio 3.96
Altman-Z 38.37
F-Score8
WACC8.95%
ROIC/WACC1.56
Cap/Depr(3y)178.7%
Cap/Depr(5y)155.64%
Cap/Sales(3y)11.2%
Cap/Sales(5y)9.67%
Profit Quality(3y)61.68%
Profit Quality(5y)71.87%
High Growth Momentum
Growth
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
EPS Next Y14.43%
EPS Next 2Y14.29%
EPS Next 3Y14.44%
EPS Next 5Y13.58%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
Revenue Next Year15.83%
Revenue Next 2Y14.84%
Revenue Next 3Y14.56%
Revenue Next 5Y12.9%
EBIT growth 1Y25.34%
EBIT growth 3Y22.76%
EBIT growth 5Y22.63%
EBIT Next Year35.45%
EBIT Next 3Y21.62%
EBIT Next 5Y17.26%
FCF growth 1Y91.03%
FCF growth 3Y37.49%
FCF growth 5Y16.85%
OCF growth 1Y25.49%
OCF growth 3Y26.68%
OCF growth 5Y15.34%

INTUITIVE SURGICAL INC / IUI1.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?

ChartMill assigns a fundamental rating of 7 / 10 to IUI1.DE.


Can you provide the valuation status for INTUITIVE SURGICAL INC?

ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.


What is the profitability of IUI1 stock?

INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 9 / 10.


How financially healthy is INTUITIVE SURGICAL INC?

The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 9 / 10.


What is the expected EPS growth for INTUITIVE SURGICAL INC (IUI1.DE) stock?

The Earnings per Share (EPS) of INTUITIVE SURGICAL INC (IUI1.DE) is expected to grow by 14.43% in the next year.